Latest Sinovant Sciences News
May 27, 2021
publication date: May 27, 2021 Sinovant Sciences, a China adults with community acquired bacterial pneumonia (CABP). The trial showed lefamulin was non-inferior to IV/oral moxifloxacin in patients with CABP. In 2017, Sinovant acquired China Vienna China Suzhou Share this with colleagues: Sorry this page is available to subscribers only. If you're not a subscriber why not subscribe today? If you are already a subscriber, please login. If you believe you should have received this message in error, please contact us .